Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect [0.03%]
溶瘤病毒递送：从纳米药动学至增强的溶瘤效应
Raquel Yokoda,Bolni M Nagalo,Brent Vernon et al.
Raquel Yokoda et al.
With the advancement of a growing number of oncolytic viruses (OVs) to clinical development, drug delivery is becoming an important barrier to overcome for optimal therapeutic benefits. Host immunity, tumor microenvironment and abnormal vas...
Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity [0.03%]
HF10对肝和腹膜转移的治愈效果由宿主抗肿瘤免疫介导
Yoshihiro Hotta,Hideki Kasuya,Itzel Bustos et al.
Yoshihiro Hotta et al.
Background: HF10 is a highly attenuated type 1 herpes simplex virus (HSV) with proven effective oncolytic effect. Previous investigations have demonstrated that colon cancer mice model treated with HF10 not only had bette...
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells [0.03%]
新城疫病毒在肿瘤和正常细胞中的促炎反应
Teridah Ernala Ginting,Jeremiah Suryatenggara,Salomo Christian et al.
Teridah Ernala Ginting et al.
Purpose: To investigate the specific role of immune responses induced by lentogenic Newcastle disease virus (NDV) for its antitumor effect. Materials and ...
Editorial announcing PubMed indexing of Oncolytic Virotherapy [0.03%]
关于Oncolytic Virotherapy被PubMed收录的编辑部公告
Faris Farassati
Faris Farassati
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [0.03%]
包括瑞吉病毒的溶瘤病毒疗法联合恶性黑色素瘤常规治疗
Hani M Babiker,Irbaz Bin Riaz,Muhammad Husnain et al.
Hani M Babiker et al.
The treatment of metastatic melanoma has evolved from an era where interferon and chemotherapy were the mainstay of treatments to an era where immunotherapy has become the frontline. Ipilimumab (IgG1 CTLA-4 inhibitor), nivolumab (IgG4 PD-1 ...
Zeeshan Ahmad,Robert A Kratzke
Zeeshan Ahmad
Oncolytic virotherapy is the use of replication-competent viruses to treat malignancies. The potential of oncolytic virotherapy as an approach to cancer therapy is based on historical evidence that certain viral infections can cause spontan...
CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter [0.03%]
利用双特异性适配体将CXCL12重定向到腺病毒载体以靶向癌细胞
Shilpa Bhatia,Samia M O&#x;Bryan,Angel A Rivera et al.
Shilpa Bhatia et al.
Ad vectors are promising delivery vehicles for cancer therapeutic interventions. However, their application is limited by promiscuous tissue tropism and hepatotoxicity. This limitation can be avoided by altering the native tropism of Ads so...
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes [0.03%]
关于talimogene laherparepvec治疗皮肤和淋巴结黑色素瘤病灶的评述
Marlana Orloff
Marlana Orloff
On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melanoma in the skin and lymph nodes. Its approval ha...
Oncolytic Seneca Valley Virus: past perspectives and future directions [0.03%]
溶细胞Seneca山谷病毒：过去观点与未来方向
Michael J Burke
Michael J Burke
Seneca Valley Virus isolate 001 (SVV-001) is an oncolytic RNA virus of the Picornaviridae family. It is also the first picornavirus discovered of the novel genus Senecavirus. SVV-001 replicates through an RNA intermediate, bypassing a DNA p...
Alicia M Waters,Gregory K Friedman,Eric K Ring et al.
Alicia M Waters et al.
Pediatric solid tumors remain a major health concern, with nearly 16,000 children diagnosed each year. Of those, ~2,000 succumb to their disease, and survivors often suffer from lifelong disability secondary to toxic effects of current trea...